Chasing a Perfusion Pressure Target Without Drowning the Lungs
A motorcyclist's brain needs a perfusion pressure the team can actually hold. Her stunned heart, not her vasculature, is what decides which vasopressor gets her there.
L.V., a 34-year-old woman, was riding home from her shift at the hospital where she works as a physical therapist when a car turned in front of her; she was helmeted, and the impact left her with bifrontal contusions and a diffuse axonal injury pattern rather than a single surgical lesion. Her ICP monitor reads 22mmHg and her cerebral perfusion pressure, unsupported, sits at 54 — below the 60 to 70mmHg range the Brain Trauma Foundation's fourth-edition guidelines recommend targeting, the range chosen specifically to avoid the higher ARDS rate Robertson and colleagues found in 1999 when CPP was pushed aggressively above 70 with fluids and pressors. Getting her from 54 into that range requires a vasopressor, and which one depends on a finding that has nothing to do with her brain directly: a bedside echocardiogram showing new, mild global hypokinesis, the catecholamine-mediated cardiac stunning that severe brain injury itself can produce even in a woman with no prior cardiac history.
Phenylephrine, a pure alpha-1 agonist, raises blood pressure through vasoconstriction alone — mechanistically simple, but it does nothing for a heart that is already pumping less effectively, and the reflex bradycardia it can trigger would only add to a cardiac output problem she doesn't need compounded. Norepinephrine combines alpha-1 vasoconstriction with meaningful beta-1 inotropic support, raising perfusion pressure through a mechanism that also helps the stunned heart generate the output that pressure is supposed to be delivering. Her brain tissue oxygen monitor, placed alongside her ICP bolt because BOOST-3 is testing whether oxygen-guided therapy improves outcomes beyond ICP-guided care alone — a question still open, since that trial has published its protocol rather than its results — currently reads 17mmHg. That is not a reassuring number: BOOST-3's own protocol treats PbtO2 above 20mmHg as the threshold to defend, so she is already below it, and the pressor chosen in the next few minutes is being asked to correct a value that has drifted rather than merely to hold a safe one. Her partner, a fellow physical therapist at the same hospital, has already asked the team directly whether the heart finding means a cardiology consult is needed independent of tonight's pressor choice — a fair question, and one the team has answered yes to, scheduled for the morning rather than folded into tonight's more time-sensitive decision.
Which pressor actually gets her there
Her hypokinesis is mild, not a full cardiogenic picture, and I'd rather start with the simpler drug. Phenylephrine gets her pressure up with one clean mechanism and no beta-agonist arrhythmia risk on top of an already-injured brain and a stunned heart. If it's not enough, we escalate.
I hear the simplicity argument, but the echo isn't an incidental finding to work around — it's telling us her cardiac output is already reduced, and phenylephrine's reflex bradycardia risk would push in exactly the wrong direction for a heart that's already pumping less. Norepinephrine raises the same perfusion pressure through a mechanism that also supports the output problem we already know she has. I don't think that's the more complicated choice here — it's the one that matches the pathophysiology we actually found.
Start norepinephrine as the primary agent, titrated to a CPP of 60 to 70 per BTF guidance rather than pushing toward the higher end Robertson's data warned against. If the dose climbs beyond a threshold we set now, add low-dose vasopressin rather than simply increasing norepinephrine further — it works through a separate receptor mechanism, so it adds pressor effect without adding more catecholamine load onto a heart that's already stunned.
Norepinephrine brought her CPP into the 60-70 range within thirty minutes, and her PbtO2 rose to 22mmHg over the following hours. Repeat echo the next day showed her hypokinesis resolving, consistent with transient catecholamine-mediated stunning rather than structural injury.
Vasopressin was never needed — her norepinephrine requirement stayed modest and never approached the pre-agreed threshold. The trauma surgeon's preference for starting with phenylephrine was not disproven by this course, since it was never trialed, and the team noted the decision was made on the strength of the echo finding rather than on how either agent would have performed head to head.